2025-12-19 - Analysis Report
Okay, here's a breakdown of the Tempus AI (TEM) stock information provided, followed by analysis:

**1) Return Rate Comparison:**

*   **TEM (Tempus AI Inc.):** Cumulative Return = 11.05%
*   **VOO (S&P 500):** Cumulative Return = 28.31%
*   **Divergence:** -7.5 (Relative Divergence: 28.8)

**Analysis:**

Tempus AI has significantly underperformed the S&P 500 over the observed period. The negative divergence indicates that TEM's cumulative return is lagging behind the S&P 500's. The relative divergence of 28.8 indicates its current position is in the lower percentile of its past divergence, suggesting it's performing relatively poorly compared to its historical performance versus the S&P 500.

**Company Overview:** Tempus AI Inc. is a technology company focused on precision medicine, using AI to personalize healthcare through data-driven insights.

**Alpha, Beta Analysis:**

*   **CAGR (2023-2025):** 11.0% -  The compounded annual growth rate is positive, but relatively low.
*   **MDD (2023-2025):** 76.7% - A very high Maximum Drawdown suggests significant volatility and risk.
*   **Alpha (2023-2025):** -16.0% - A negative Alpha indicates underperformance relative to its benchmark (likely the S&P 500) after accounting for risk.
*   **Beta (2023-2025):** 0.3 - A Beta less than 1 suggests the stock is less volatile than the market overall, which contradicts the MDD.
*   **Cap (B):** 11.1 - Market capitalization of $11.1 billion

**Analysis:** The historical data shows TEM has underperformed the market significantly based on the Alpha metric. The high MDD indicates significant risk for investors.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** $62.21
*   **Previous Close:** $64.615
*   **Change:** -3.72%
*   **5-day SMA:** 66.843
*   **20-day SMA:** 72.926
*   **60-day SMA:** 80.3397

**Analysis:** The stock price is currently below all three Simple Moving Averages (5-day, 20-day, and 60-day). This indicates a short-term, medium-term, and long-term downtrend. The recent price drop (-3.72%) reinforces this downward momentum.

**3) Indicator Analysis:**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI (Relative Strength Index):** 12.66 (Oversold)
*   **PPO (Percentage Price Oscillator):** -1.4225
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -11.0 (Short-term decline)
*   **Expected Return (%):** NaN (Not a Number - No data provided to calculate)

**Analysis:**

*   The MRI of 0.7 suggests a medium investment recommendation, but this needs to be considered alongside other factors.
*   The RSI of 12.66 indicates the stock is heavily oversold, which *could* signal a potential for a short-term rebound, but should not be relied upon in isolation.
*   The negative PPO value reinforces the downtrend.
*   The Hybrid Signal recommendation is to buy with a 100% cash allocation.
*   The negative divergence change confirms recent underperformance.
*   The "Expected Return" is unavailable, making it impossible to assess potential long-term gains.

**4) Recent News & Significant Events:**

*   **Executive Selling Shares:** EVP Erik Phelps sold shares, which can sometimes be interpreted negatively by the market (insider selling).
*   **Seeking Alpha Article:** "Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant" - Highlights potential but also acknowledges the high-risk nature.
*   **Quiver Quantitative:** Mentions opinions on FDA clearance and earnings report. FDA Clearance for AI Diagnostics Might Change The Case For Investing In Tempus AI (TEM) - The FDA clearance is generally viewed as a positive catalyst.
*   **Yahoo Finance Article:** TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom? - Comparing TEM to a competitor.
*   **Simply Wall St.:** "FDA Clearance for AI Diagnostics Might Change The Case For Investing In Tempus AI (TEM)" - Highlights potential positive impact of FDA clearance.
*   **Benzinga:** "Top 3 Health Care Stocks You'll Regret Missing This Quarter" - TEM may or may not be one of the mentioned stocks.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~2.14)
*   **Target Price:** Average $90.17 (High $105.00 / Low $80.00)

**Analysis:** Analyst consensus is positive, with a "Buy" rating and a significant target price upside from the current price.

**5) Comprehensive Analysis:**

Tempus AI (TEM) is a high-growth, high-risk stock. While analysts have a positive outlook and the company is pursuing AI-driven healthcare solutions, several factors raise concerns:

*   **Underperformance:** TEM has significantly underperformed the S&P 500, evidenced by negative Alpha and divergence.
*   **Downtrend:**  The stock is currently in a downtrend, trading below its SMAs.
*   **Volatility:** A high MDD indicates substantial price swings.
*   **Insider Selling:** Recent selling by an executive could be a negative signal.

**However, there are also potential positives:**

*   **Oversold Condition:** The RSI indicates the stock might be oversold, offering a potential short-term rebound.
*   **FDA Clearance:** Recent FDA clearance is a positive catalyst that could drive future growth.
*   **Analyst Optimism:** Analysts remain largely bullish, with a "Buy" consensus and a high target price.
*   **Hybrid signal:** Recommends investors to continue buying the stock.

**In conclusion:** TEM presents a mixed picture. While there are positive catalysts and potential for long-term growth, the stock is currently in a downtrend and exhibits high volatility. The decision to invest in TEM should be based on an investor's risk tolerance and belief in the company's long-term vision. It is crucial to do thorough due diligence, carefully weighing the risks and potential rewards. The high analyst target price suggests considerable upside, but that hinges on the company successfully executing its growth strategy and achieving profitability. It may be beneficial to wait for more positive price action and evidence of a trend reversal before considering an investment.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.